Literature DB >> 22586649

NF-κB in cancer: a matter of life and death.

Bharat B Aggarwal1, Bokyung Sung.   

Abstract

Activation of NF-κB has been linked to various cellular processes in cancer, including inflammation, transformation, proliferation, angiogenesis, invasion, metastasis, chemoresistance, and radioresistance. Although acute inflammation mediates innate and humoral immunity, chronic inflammation has been linked to tumorigenesis. Thus, inhibition of NF-κB has therapeutic potential in sensitization of tumors to chemotherapeutic agents; however, generalized suppression of NF-κB can result in serious host toxicity with minimum effect on the tumor.
© 2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22586649      PMCID: PMC3392037          DOI: 10.1158/2159-8290.CD-11-0260

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  14 in total

1.  The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer.

Authors:  Thomas A Buchholz; Amit K Garg; Nitin Chakravarti; Bharat B Aggarwal; Francisco J Esteva; Henry M Kuerer; S Eva Singletary; Gabriel N Hortobagyi; Lajos Pusztai; Massimo Cristofanilli; Aysegul A Sahin
Journal:  Clin Cancer Res       Date:  2005-12-01       Impact factor: 12.531

2.  Cell-selective inhibition of NF-κB signaling improves therapeutic index in a melanoma chemotherapy model.

Authors:  Thomas Enzler; Yasuyo Sano; Min-Kyung Choo; Howard B Cottam; Michael Karin; Hensin Tsao; Jin Mo Park
Journal:  Cancer Discov       Date:  2011-11       Impact factor: 39.397

3.  Constitutive IkappaB kinase activity correlates with nuclear factor-kappaB activation in human melanoma cells.

Authors:  J Yang; A Richmond
Journal:  Cancer Res       Date:  2001-06-15       Impact factor: 12.701

Review 4.  Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs.

Authors:  Chikashi Nakanishi; Masakazu Toi
Journal:  Nat Rev Cancer       Date:  2005-04       Impact factor: 60.716

5.  Association of activated transcription factor nuclear factor kappab with chemoradiation resistance and poor outcome in esophageal carcinoma.

Authors:  Julie G Izzo; Usha Malhotra; Tsung-Teh Wu; Joe Ensor; Rajyalakshmi Luthra; Jeffrey H Lee; Stephen G Swisher; Zhongxing Liao; K S Clifford Chao; Walter N Hittelman; Bharat B Aggarwal; Jaffer A Ajani
Journal:  J Clin Oncol       Date:  2006-01-09       Impact factor: 44.544

6.  Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy.

Authors:  Mario Scartozzi; Italo Bearzi; Chiara Pierantoni; Alessandra Mandolesi; Fotios Loupakis; Alberto Zaniboni; Vincenzo Catalano; Antonello Quadri; Fausto Zorzi; Rossana Berardi; Tommasina Biscotti; Roberto Labianca; Alfredo Falcone; Stefano Cascinu
Journal:  J Clin Oncol       Date:  2007-09-01       Impact factor: 44.544

Review 7.  Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe.

Authors:  Bharat B Aggarwal; R V Vijayalekshmi; Bokyung Sung
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

Review 8.  Nuclear factor-kappaB: the enemy within.

Authors:  Bharat B Aggarwal
Journal:  Cancer Cell       Date:  2004-09       Impact factor: 31.743

9.  KINK-1, a novel small-molecule inhibitor of IKKbeta, and the susceptibility of melanoma cells to antitumoral treatment.

Authors:  Margarete Schön; B Gregor Wienrich; Susanne Kneitz; Helga Sennefelder; Katharina Amschler; Verena Vöhringer; Olaf Weber; Thorsten Stiewe; Karl Ziegelbauer; Michael P Schön
Journal:  J Natl Cancer Inst       Date:  2008-06-10       Impact factor: 13.506

Review 10.  Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets.

Authors:  Bharat B Aggarwal; Bokyung Sung
Journal:  Trends Pharmacol Sci       Date:  2008-12-26       Impact factor: 14.819

View more
  62 in total

Review 1.  Cancer drug development: The missing links.

Authors:  Ajaikumar B Kunnumakkara; Devivasha Bordoloi; Bethsebie Lalduhsaki Sailo; Nand Kishor Roy; Krishan Kumar Thakur; Kishore Banik; Mehdi Shakibaei; Subash C Gupta; Bharat B Aggarwal
Journal:  Exp Biol Med (Maywood)       Date:  2019-04-08

Review 2.  Applications of RNA interference in the treatment of arthritis.

Authors:  Muhammad Farooq Rai; Hua Pan; Huimin Yan; Linda J Sandell; Christine T N Pham; Samuel A Wickline
Journal:  Transl Res       Date:  2019-07-10       Impact factor: 7.012

3.  TAB3 overexpression promotes cell proliferation in non-small cell lung cancer and mediates chemoresistance to CDDP in A549 cells via the NF-κB pathway.

Authors:  Jie Chen; Jun Gu; Jian Feng; Yifei Liu; Qun Xue; Tingting Ni; Zhiwen Wang; Liangliang Jia; Guoxin Mao; Lili Ji
Journal:  Tumour Biol       Date:  2015-10-17

4.  Tumor suppressor ING4 overexpression contributes to proliferation and invasion inhibition in gastric carcinoma by suppressing the NF-κB signaling pathway.

Authors:  Shijie Li; Tianli Fan; Hongtao Liu; Jiangtao Chen; Changjiang Qin; Xuequn Ren
Journal:  Mol Biol Rep       Date:  2013-09-22       Impact factor: 2.316

Review 5.  Long non-coding RNAs and nuclear factor-κB crosstalk in cancer and other human diseases.

Authors:  Subash C Gupta; Nikee Awasthee; Vipin Rai; Srinivas Chava; Venugopal Gunda; Kishore B Challagundla
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2019-10-19       Impact factor: 10.680

6.  Involvement of NF-κB in mediating the anti-tumour effects of combretastatins in T cells.

Authors:  Jade K Pollock; Lisa M Greene; Seema M Nathwani; Paula Kinsella; Niamh M O'Boyle; Mary J Meegan; Daniela M Zisterer
Journal:  Invest New Drugs       Date:  2018-02-19       Impact factor: 3.850

7.  [Effects of farnesyltransferase silencing on the migration and invasion of tongue squamous cell carcinoma].

Authors:  Shan-Gui Sheng; Ya-Nan Wang; Shao-Ru Wang; Kai Zhao; Yun-Ying Wang; Xiao-Na Xu; Qi-Min Wang; Lei Tong; Zheng-Gang Chen
Journal:  Hua Xi Kou Qiang Yi Xue Za Zhi       Date:  2020-04-01

8.  Regulation of anoikis by deleted in breast cancer-1 (DBC1) through NF-κB.

Authors:  Sun Hee Park; Philip Riley; Steven M Frisch
Journal:  Apoptosis       Date:  2013-08       Impact factor: 4.677

Review 9.  Multidrug-resistant cancer cells and cancer stem cells hijack cellular systems to circumvent systemic therapies, can natural products reverse this?

Authors:  Qian Zhang; Yunjiang Feng; Derek Kennedy
Journal:  Cell Mol Life Sci       Date:  2016-09-12       Impact factor: 9.261

10.  Artemisinin triggers a G1 cell cycle arrest of human Ishikawa endometrial cancer cells and inhibits cyclin-dependent kinase-4 promoter activity and expression by disrupting nuclear factor-κB transcriptional signaling.

Authors:  Kalvin Q Tran; Antony S Tin; Gary L Firestone
Journal:  Anticancer Drugs       Date:  2014-03       Impact factor: 2.248

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.